title: Genomic heterogeneity in multiple myeloma.
abstract: Multiple myeloma (MM) is an incurable malignancy in majority of patients characterized by clonal proliferation of plasma cells. To date, treatment is established based on general conditions and age of patients. However, MM is a heterogeneous disease, featured by various subtypes and different outcomes. Thus, the understanding of MM biology is currently a major challenge to eventually cure the disease. During the last decade, karyotype studies and gene expression profiling have identified robust prognostic markers as well as a widespread genomic landscape. More recently, studies of epigenetic, transcriptional modifications and next generation sequencing have allowed characterization of critical genes and pathways, clonal heterogeneity and mutational profiles involved in myelomagenesis. Altogether, these findings constitute important tools to develop new targeted and personalized therapies in MM.
authors.affiliation: Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
authors.forename: Raphaël
authors.initials: R
authors.lastname: Szalat
authors.affiliation: Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States; VA Boston Healthcare System, Boston, MA, United States. Electronic address: nikhil_munshi@dfci.harvard.edu.
authors.forename: Nikhil C
authors.initials: NC
authors.lastname: Munshi
mesh_terms: D044127:Epigenesis, Genetic; D020869:Gene Expression Profiling; D018740:Genetic Heterogeneity; D006801:Humans; D035683:MicroRNAs / Q000235:genetics; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics*; D009154:Mutation
chemical_list: D035683:MicroRNAs